Company: ACBM
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001640334-25-001347
Chunk: 13

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-08-05
Form: 10-Q
Item: Item 1
Chunk 13
---
 of period $26  $926 

Cash used in operating activities of $116,515 for the six months ended June 30, 2025 reflected primarily our net loss of $25,863 reduced by an increase in prepaid expenses of $35,000 relating to professional fees and decrease in accounts payable and accrued expenses of $58,967 and increased by imputed interest – related parties of $3,315.

Cash used in operating activities of $19,842 for the six months ended June 30, 2024 reflected primarily our net loss of $21,395, increased primarily by imputed interest of $2,011, a reduction of prepaid expenses of $1,250 and decreased by a reduction of accounts payable and accrued expenses of $1,708.

Cash provided by financing activities for the six months ended June 30, 2025 and 2024 reflected advances from a minority stockholder. These advances provided us with funds to cover our cash used in operations.

 13Table of Contents

Going Concern

The accompanying financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We had minimal cash as of June 30, 2025, we have had no revenue subsequent to December 31, 2022 through the date of this report, and we incurred a loss from operations for the six months ended June 30, 2025, the years ended December 31, 2024 and 2023 as well as prior years, had negative cash flow from operations for the six months ended June 30, 2025 and the years ended December 31, 2024 and 2023. To date, we did not generate any revenue subsequent to December 31, 2022 and did not develop any products from our research and development activities during the period from May 2021 through August 2023.  Further, our common stock is presently traded on the OTC Market Group’s Pink Limited Market.  Our common stock was previously listed on the OTC Market Group’s Expert Market, as a result of which our common stock was not eligible for proprietary broker-dealer quotes.  There are no market makers for our common stock.  At present, our stock is not eligible for proprietary broker-dealer quotations and all quotes reflect unsolicited customer orders.  Unsolicited only stocks have a higher risk of wider spreads, increased volatility, and